Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

This historic event marks the availability of the first pharmacologic treatment for women suffering from HSDD. We applaud the FDA for recognizing female sexual disorders as one of their top 20 conditions for which there is unmet medical need and for making their decision to approve flibanserin based on science. We are optimistic that this approval will stimulate more research and drug development for HSDD and other female sexual disorders for which therapeutic options are greatly needed.

We also extend robust gratitude to many of our leaders and members who played a critical role in this long awaited advancement in women’s health care. By serving on the FDA Advisory Panel, speaking for the sponsor at the FDA, testifying at the Open Public Hearings, and caring for patients who suffer from sexual disorders without approved medical treatment options, ISSWSH members provided broad expertise, invested countless hours, and contributed in many ways to this monumental leap forward in sexual medicine.

Flibanserin will be marketed with the trade name Addyi. As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, ISSWSH is poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies for HSDD. Through our robust educational infrastructure, we will help to ensure appropriate, safe, and selective treatment of HSDD with Addyi, now that approval has finally arrived!

Most sincerely,

Sharon J. Parish, MD, IF, NCMP
ISSWSH President, 2014-2016

Sheryl A. Kingsberg, PhD, IF
Chair, ISSWSH Advocacy Committee

DOWNLOAD OUR PRESS RELEASE

Save the Date

ISSWSH Annual Meeting 2021

March 5-7, 2021  
Virtual
Registration open for on-demand viewing

ISSWSH Fall Course 2021

October 7-10, 2021   116 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2022

March 3-6, 2022   266 days left
Renaissance Dallas Hotel - Dallas, TX
Visit the Meeting Website

Latest Tweets

Women's sexual health is not a niche! The global femtech market is estimated to grow to over $3.04 billion by the… https://t.co/W00JvAjMLU ISSWSH
Tools of the Patriarchy: The Weaponization of Sexual Freedom. #sexuallib https://t.co/i75LzLIw9C ISSWSH
IOSS is hosting a special online symposium on June 25 in memory of friend & colleague, Dr. Ariel Gustavo Scafuri. F… https://t.co/66KGiexNt3 ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram